JPWO2020053664A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2020053664A5 JPWO2020053664A5 JP2021513996A JP2021513996A JPWO2020053664A5 JP WO2020053664 A5 JPWO2020053664 A5 JP WO2020053664A5 JP 2021513996 A JP2021513996 A JP 2021513996A JP 2021513996 A JP2021513996 A JP 2021513996A JP WO2020053664 A5 JPWO2020053664 A5 JP WO2020053664A5
- Authority
- JP
- Japan
- Prior art keywords
- combination
- pharmaceutical composition
- therapeutic agent
- subject
- inhibitor
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000008194 pharmaceutical composition Substances 0.000 claims 22
- 239000003814 drug Substances 0.000 claims 12
- 229940124597 therapeutic agent Drugs 0.000 claims 10
- 229940124297 CDK 4/6 inhibitor Drugs 0.000 claims 3
- 229940125763 bromodomain inhibitor Drugs 0.000 claims 3
- 150000001875 compounds Chemical class 0.000 claims 3
- 102000015694 estrogen receptors Human genes 0.000 claims 3
- 108010038795 estrogen receptors Proteins 0.000 claims 3
- 206010006187 Breast cancer Diseases 0.000 claims 2
- 208000026310 Breast neoplasm Diseases 0.000 claims 2
- VWUXBMIQPBEWFH-WCCTWKNTSA-N Fulvestrant Chemical group OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3[C@H](CCCCCCCCCS(=O)CCCC(F)(F)C(F)(F)F)CC2=C1 VWUXBMIQPBEWFH-WCCTWKNTSA-N 0.000 claims 2
- 229950001573 abemaciclib Drugs 0.000 claims 2
- 239000013078 crystal Substances 0.000 claims 2
- 230000000593 degrading effect Effects 0.000 claims 2
- 229940079593 drug Drugs 0.000 claims 2
- 229960002258 fulvestrant Drugs 0.000 claims 2
- UZWDCWONPYILKI-UHFFFAOYSA-N n-[5-[(4-ethylpiperazin-1-yl)methyl]pyridin-2-yl]-5-fluoro-4-(7-fluoro-2-methyl-3-propan-2-ylbenzimidazol-5-yl)pyrimidin-2-amine Chemical group C1CN(CC)CCN1CC(C=N1)=CC=C1NC1=NC=C(F)C(C=2C=C3N(C(C)C)C(C)=NC3=C(F)C=2)=N1 UZWDCWONPYILKI-UHFFFAOYSA-N 0.000 claims 2
- 229960004390 palbociclib Drugs 0.000 claims 2
- AHJRHEGDXFFMBM-UHFFFAOYSA-N palbociclib Chemical group N1=C2N(C3CCCC3)C(=O)C(C(=O)C)=C(C)C2=CN=C1NC(N=C1)=CC=C1N1CCNCC1 AHJRHEGDXFFMBM-UHFFFAOYSA-N 0.000 claims 2
- 229940095743 selective estrogen receptor modulator Drugs 0.000 claims 2
- 239000000333 selective estrogen receptor modulator Substances 0.000 claims 2
- VUFGOHIETLJZRG-UHFFFAOYSA-N 1-benzyl-6-(3,5-dimethyl-1,2-oxazol-4-yl)-N-methylimidazo[4,5-b]pyridin-2-amine Chemical compound C(C1=CC=CC=C1)N1C(=NC2=NC=C(C=C21)C=1C(=NOC=1C)C)NC VUFGOHIETLJZRG-UHFFFAOYSA-N 0.000 claims 1
- OEPMGQATBAQVFK-UHFFFAOYSA-N 1-benzyl-6-(3,5-dimethyl-1,2-oxazol-4-yl)imidazo[4,5-b]pyridin-2-amine Chemical compound C(C1=CC=CC=C1)N1C(=NC2=NC=C(C=C21)C=1C(=NOC=1C)C)N OEPMGQATBAQVFK-UHFFFAOYSA-N 0.000 claims 1
- RHXHGRAEPCAFML-UHFFFAOYSA-N 7-cyclopentyl-n,n-dimethyl-2-[(5-piperazin-1-ylpyridin-2-yl)amino]pyrrolo[2,3-d]pyrimidine-6-carboxamide Chemical group N1=C2N(C3CCCC3)C(C(=O)N(C)C)=CC2=CN=C1NC(N=C1)=CC=C1N1CCNCC1 RHXHGRAEPCAFML-UHFFFAOYSA-N 0.000 claims 1
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 claims 1
- 238000002512 chemotherapy Methods 0.000 claims 1
- 231100000371 dose-limiting toxicity Toxicity 0.000 claims 1
- 238000009169 immunotherapy Methods 0.000 claims 1
- 238000011275 oncology therapy Methods 0.000 claims 1
- 229950003687 ribociclib Drugs 0.000 claims 1
- 150000003839 salts Chemical class 0.000 claims 1
- 206010043554 thrombocytopenia Diseases 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862730837P | 2018-09-13 | 2018-09-13 | |
| US62/730,837 | 2018-09-13 | ||
| PCT/IB2019/001035 WO2020053664A1 (en) | 2018-09-13 | 2019-09-13 | Combination therapy for the treatment of estrogen-receptor positive breast cancer |
Publications (4)
| Publication Number | Publication Date |
|---|---|
| JP2022500423A JP2022500423A (ja) | 2022-01-04 |
| JPWO2020053664A5 true JPWO2020053664A5 (https=) | 2022-09-22 |
| JP2022500423A5 JP2022500423A5 (https=) | 2022-09-22 |
| JP7441213B2 JP7441213B2 (ja) | 2024-02-29 |
Family
ID=69777646
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021513996A Active JP7441213B2 (ja) | 2018-09-13 | 2019-09-13 | エストロゲン受容体陽性乳癌の治療のための併用療法 |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US20220047563A1 (https=) |
| EP (1) | EP3849550B1 (https=) |
| JP (1) | JP7441213B2 (https=) |
| CN (1) | CN112912078B (https=) |
| CA (1) | CA3110788A1 (https=) |
| ES (1) | ES2993363T3 (https=) |
| TW (1) | TWI841598B (https=) |
| WO (1) | WO2020053664A1 (https=) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI882964B (zh) | 2018-09-13 | 2025-05-11 | 大陸商恒翼生物醫藥（上海）股份有限公司 | Bet 溴結構域(bromodomain)抑制劑之固體形式之製備方法 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2015505562A (ja) * | 2012-01-31 | 2015-02-23 | ノバルティス アーゲー | Ｒｔｋ阻害剤と抗エストロゲン剤との組合せ、およびがん治療のためのその使用 |
| WO2014128655A1 (en) * | 2013-02-25 | 2014-08-28 | Aurigene Discovery Technologies Limited | Substituted imidazo[4,5-c]quinoline derivatives as bromodomain inhibitors |
| CA2915838C (en) * | 2013-06-21 | 2023-04-18 | Zenith Epigenetics Corp. | Bicyclic bromodomain inhibitors |
| JP6553632B2 (ja) * | 2013-11-18 | 2019-07-31 | フォーマ セラピューティクス，インコーポレイテッド | Ｂｅｔブロモドメイン阻害剤としてのテトラヒドロキノリン組成物 |
| WO2016203335A1 (en) * | 2015-06-18 | 2016-12-22 | Pfizer Inc. | Novel pyrido[2,3-b]pyrazinones as bet-family bromodomain inhibitors |
| WO2017015027A1 (en) * | 2015-07-20 | 2017-01-26 | Mayo Foundation For Medical Education And Research | Methods and materials for treating cancer |
| WO2018097977A1 (en) * | 2016-11-22 | 2018-05-31 | Gilead Sciences, Inc. | Crystalline forms of a phosphate complex of a bet inhibitor |
| WO2018106444A1 (en) * | 2016-12-06 | 2018-06-14 | Gilead Sciences, Inc. | Treatment of breast cancer by concomitant administration of a bromodomain inhibitor and a second agent |
| WO2018106433A1 (en) * | 2016-12-06 | 2018-06-14 | Gilead Sciences, Inc. | Treatment of prostate cancer by concomitant administration of a bromodomain inhibitor and a second agent |
| EP3758753A1 (en) * | 2018-02-27 | 2021-01-06 | Pfizer Inc | Combination of a cyclin dependent kinase inhibitor and a bet-bromodomain inhibitor |
-
2019
- 2019-09-12 TW TW108133098A patent/TWI841598B/zh active
- 2019-09-13 CN CN201980059916.5A patent/CN112912078B/zh active Active
- 2019-09-13 ES ES19861171T patent/ES2993363T3/es active Active
- 2019-09-13 CA CA3110788A patent/CA3110788A1/en active Pending
- 2019-09-13 WO PCT/IB2019/001035 patent/WO2020053664A1/en not_active Ceased
- 2019-09-13 EP EP19861171.7A patent/EP3849550B1/en active Active
- 2019-09-13 JP JP2021513996A patent/JP7441213B2/ja active Active
- 2019-09-13 US US17/275,462 patent/US20220047563A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR101892788B1 (ko) | 벤다무스틴과 조합된 히스톤 디아세틸라제 억제제의 제제 및 그의 용도 | |
| JPWO2020053655A5 (https=) | ||
| JP2015512406A5 (https=) | ||
| JP2013511507A5 (https=) | ||
| JP2019081792A5 (https=) | ||
| CN1444478A (zh) | 塞利克西组合物在快速缓解疼痛中的用途 | |
| CN107530317A (zh) | 大麻素类和n‑酰基乙醇胺的组合 | |
| JP2016528162A (ja) | がんの治療のための併用療法としてのエリブリンおよびレンバチニブの使用 | |
| JP2012515184A (ja) | 大腸がんの治療方法 | |
| JP2015528501A5 (https=) | ||
| JP2015517523A5 (https=) | ||
| JP2021509395A5 (https=) | ||
| AU2015301097A1 (en) | Drug combinations to treat multiple myeloma | |
| RU2017128616A (ru) | Комбинированное лекарственное средство | |
| JP2019530706A5 (https=) | ||
| RU2013154355A (ru) | Способ лечения мезотелиомы ингибитором рi3к | |
| US20060004076A1 (en) | Co-administration of dehydroepiandrosterone (DHEA) congener with pharmaceutically active agents for treating inflammation | |
| JPWO2013058303A1 (ja) | 医薬組成物 | |
| JP2020504129A (ja) | 非アルコール性脂肪性肝炎（ｎａｓｈ）および肝線維症のための併用療法 | |
| JP2022500431A5 (https=) | ||
| JP2016505050A5 (https=) | ||
| JP2021505669A5 (https=) | ||
| CN102688493B (zh) | 含有白藜芦醇及白藜芦醇类衍生物和Bc1-2抑制剂的药物组合物及其应用 | |
| JP2022500423A5 (https=) | ||
| ES2286716T3 (es) | Composicion farmaceutica de liberacion controlada y proceso para preparar la misma. |